Key result
A staging system combining primary tumour necrosis and growth-rate index identified groups with good (79-94%), intermediate (61%), and exceptionally poor (6%) 2-year metastasis-free survival.
Why the study?
Does a staging system combining primary tumour necrosis and growth-rate index (GRI) predict metastasis-free survival in adult patients with locally recurrent soft-tissue sarcoma?
Population
460 adult patients with soft-tissue sarcomas of the extremities and trunk wall diagnosed and treated between…
Design
Cohort
Follow-up
2 years
Authors
Loading...
May aid risk stratification for adjuvant trials in recurrent sarcoma; leaves open prospective validation before clinical use.
Cohort (n=460)
Does a staging system combining primary tumour necrosis and growth-rate index (GRI) predict metastasis-free survival in adult patients with locally recurrent soft-tissue sarcoma?
A staging system combining primary tumour necrosis and the growth-rate index of local recurrence effectively stratifies survival in patients with locally recurrent soft-tissue sarcoma, identifying candidates for adjuvant chemotherapy trials.
Choong et al. (1995) conducted a cohort in Soft-tissue sarcoma of the extremities and trunk wall (n=460). Staging system based on primary tumour necrosis and growth-rate index (GRI) was evaluated on Metastasis-free survival. A staging system combining primary tumour necrosis and growth-rate index identified groups with good (79-94%), intermediate (61%), and exceptionally poor (6%) 2-year metastasis-free survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: